news
Novoeight® (turoctocog alfa) receives approval from the FDA
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
List view / Grid view
Novo Nordisk
news
IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
news
Enrolment of Victoza® (liraglutide) cardiovascular outcomes trial completed on schedule
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
news
NovoEight® (turoctocog alfa) receives positive opinion from the European regulatory authorities
20 September 2013 | By Novo Nordisk
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on its recombinant factor VIII product turoctocog alfa, with the intended brand name NovoEight®...
news
Novo Nordisk increased operating profit by 15% in the first six months of 2013
8 August 2013 | By Novo Nordisk
Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir®...
news
Global study finds one in five feel discriminated against because of their diabetes
24 June 2013 | By Novo Nordisk
Key results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™)...
news
New retrospective analysis supports clinical data – Victoza® provides improved blood sugar control compared to sitagliptin and exenatide
22 June 2013 | By Novo Nordisk
Findings from a new real-world study...
news
Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes
31 May 2013 | By Novo Nordisk
Novo Nordisk announced the submission to the EMA of the MAA for the approval of IDegLira...
news
Novo Nordisk supports new global commitment to fight noncommunicable diseases
30 May 2013 | By Novo Nordisk
The World Health Assembly unanimously adopted a global action plan...
news
Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
17 May 2013 | By Novo Nordisk
Novo Nordisk announced the completion of paradigm™ 2...
news
Novo Nordisk invests DKK 380 million in its Kalundborg plant
6 May 2013 | By Novo Nordisk
Novo Nordisk is investing an additional 380 million Danish kroner in its Kalundborg plant in Denmark...
news
Diabetes on the agenda in Mexico
9 April 2013 | By Novo Nordisk
The first-ever Diabetes Forum takes place in Mexico City (9th April), to address the critical diabetes challenge the country is facing...
news
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
news
Novo Nordisk’s award-winning NovoPen® 5 with easy-to-use memory function approved in China
7 March 2013 | By Biosector 2
NovoPen® 5 has just been approved for launch in China...
news
In Nigeria, a new project prompts easier insulin access
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
